# ESLA (Estrella Immunopharma, Inc.) - SEC EDGAR Financial Statements

> Estrella Immunopharma, Inc. reported $1.67M in total assets and a net loss of $12.59M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/ESLA
- Markdown: https://convexityos.com/fundamentals/ESLA.md
- SEC CIK: 0001844417
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:01 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001844417&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$12.55M | Operating profit |
| Net Income | FY 2025 | -$12.59M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$0.29 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $100K | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Research & Development | $10.25M | $4.11M | $10.45M | -- | -- |
| Total Operating Expenses | $13.06M | $7.31M | $11.11M | -- | -- |
| **Operating Income** | -$13.06M | -$7.31M | -$11.11M | -$1.57M | -$249K |
| Interest Income | -- | -- | -- | $654K | $1.4K |
| Income Before Tax | -$13.06M | -$7.31M | -$11.11M | -$915K | -$248K |
| Income Tax Expense | $838 | $1.6K | -- | $81K | $0 |
| **Net Income** | -$13.06M | -$7.31M | -$11.11M | -$996K | -$248K |
| Basic EPS | -$0.35 | -$0.27 | -$36.35 | -- | -- |
| **Diluted EPS** | -$0.35 | -$0.27 | -$36.35 | -- | -- |
| Basic Shares Outstanding | 36.8M | 27.1M | 305.7K | -- | 1.2M |
| Diluted Shares Outstanding | 36.8M | 27.1M | 305.7K | -- | 1.2M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $6.90M | $1.40M | $1.40M | $25K | $4.15M | $4.66M | $1.41M | $33K |
| Total Operating Expenses | $7.50M | $2.08M | $2.29M | $680K | $4.73M | $5.54M | $2.10M | $1.05M |
| **Operating Income** | -$7.50M | -$2.08M | -$2.29M | -$680K | -$4.73M | -$5.54M | -$2.10M | -$1.05M |
| Income Before Tax | -$7.38M | -$2.31M | -$2.29M | -$613K | -$4.80M | -$5.54M | -$2.10M | -$1.05M |
| Income Tax Expense | -- | -- | -- | -$25 | $0 | $850 | $13 | -- |
| **Net Income** | -$7.38M | -$2.31M | -$2.29M | -$613K | -$4.80M | -$5.54M | -$2.10M | -$1.05M |
| Basic EPS | -$0.17 | -$0.05 | -$0.05 | -- | -$0.13 | -$0.15 | -$0.06 | -- |
| **Diluted EPS** | -$0.17 | -$0.05 | -$0.05 | -- | -$0.13 | -$0.15 | -$0.06 | -- |
| Basic Shares Outstanding | 43.6M | 43.0M | 42.1M | -- | 37.1M | 36.2M | 36.2M | -- |
| Diluted Shares Outstanding | 43.6M | 43.0M | 42.1M | -- | 37.1M | 36.2M | 36.2M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $1.38M | $917K | $4.17M | $2.48M | $41K | $479K |
| **Cash & Short-Term Investments** | $1.38M | $917K | $4.17M | $2.48M | $41K | $479K |
| Accounts Receivable, Net | -- | -- | -- | $273K | -- | -- |
| **Total Current Assets** | $1.68M | $1.64M | $4.45M | $2.75M | $52K | $616K |
| **Total Non-Current Assets** | $1.50M | $1.50M | $0 | $276K | $9.67M | $45.19M |
| **Total Assets** | $3.18M | $3.14M | $4.45M | $3.03M | $9.72M | $45.80M |
| **Total Current Liabilities** | $13.54M | $3.00M | $181K | $9.76M | $1.07M | $73K |
| Other Non-Current Liabilities | -- | -- | -- | $13K | -- | -- |
| **Total Non-Current Liabilities** | $0 | $0 | $0 | $13K | $1.58M | $1.55M |
| **Total Liabilities** | $13.54M | $3.00M | $181K | $9.77M | $2.65M | $1.62M |
| Common Stock | $3.8K | $3.7K | $3.7K | $98 | $142 | $142 |
| Retained Earnings | -$36.99M | -$23.93M | -$19.50M | -$12.19M | -$2.26M | -$1.01M |
| **Total Stockholders' Equity** | -$10.37M | $144K | $4.27M | -$11.74M | -$6.48M | -$1.01M |
| Total Equity | -$10.37M | $144K | $4.27M | -$11.74M | -$6.48M | -$1.01M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $100K | $100K | -- | $1.38M | $1.63M | $1.32M | $421K | $917K |
| **Cash & Short-Term Investments** | $100K | $100K | -- | $1.38M | $1.63M | $1.32M | $421K | $917K |
| **Total Current Assets** | $1.67M | $1.82M | $2.16M | $1.68M | $2.02M | $1.48M | $944K | $1.64M |
| **Total Non-Current Assets** | $0 | $0 | $1.50M | $1.50M | $1.50M | $1.50M | $1.50M | $1.50M |
| **Total Assets** | $1.67M | $1.82M | $3.66M | $3.18M | $3.52M | $2.98M | $2.44M | $3.14M |
| **Total Current Liabilities** | $15.64M | $9.26M | $8.93M | $13.54M | $13.36M | $9.08M | $4.28M | $3.00M |
| **Total Non-Current Liabilities** | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Total Liabilities** | $15.64M | $9.26M | $8.93M | $13.54M | $13.36M | $9.08M | $4.28M | $3.00M |
| Common Stock | $4.4K | $4.4K | $4.3K | $3.8K | $3.8K | $3.8K | $3.7K | $3.7K |
| Retained Earnings | -$48.97M | -$41.59M | -$39.28M | -$36.99M | -$36.38M | -$31.58M | -$26.03M | -$23.93M |
| **Total Stockholders' Equity** | -$13.97M | -$7.43M | -$5.27M | -$10.37M | -$9.84M | -$6.09M | -$1.83M | $144K |
| Total Equity | -$13.97M | -$7.43M | -$5.27M | -$10.37M | -$9.84M | -$6.09M | -$1.83M | $144K |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Net Income | -$13.06M | -$7.31M | -$11.11M | -$996K | -$248K |
| Stock-Based Compensation | $619K | $1.19M | $410K | -- | -- |
| **Operating Cash Flow** | -$1.79M | -$16.07M | -$1.34M | -$1.04M | -$316K |
| **Investing Cash Flow** | -- | $4.96M | -$273K | $36.17M | -$45.19M |
| Common Stock Issued | $2.40M | -- | -- | -- | $25K |
| Share Repurchases | -$29K | -- | -- | -- | -- |
| **Financing Cash Flow** | $2.25M | $12.79M | -- | -$35.56M | $45.98M |
| **Net Change in Cash** | $467K | $1.69M | -$1.61M | -$438K | $479K |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$7.38M | -$2.31M | -$2.29M | -$613K | -$4.80M | -$5.54M | -$2.10M | -$1.05M |
| Stock-Based Compensation | $106K | $145K | $147K | $148K | $152K | $159K | $159K | $432K |
| **Operating Cash Flow** | -$217K | -$1.78M | -$6.70M | -$177K | -$727K | -$415K | -$466K | -$896K |
| Common Stock Issued | $0 | $0 | $8.00M | -- | -- | -- | -- | -- |
| Share Repurchases | -- | -- | -- | $0 | $0 | $0 | -$29K | -- |
| **Financing Cash Flow** | $163K | $4 | $7.24M | -$65K | $1.04M | $1.31M | -$29K | $15K |
| **Net Change in Cash** | -$54K | -$1.78M | $543K | -$242K | $310K | $895K | -$495K | -$881K |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -- | -171.1% | -- | -- | -- |
| Return on Assets (ROA) | -411.2% | -164.2% | -367.0% | -10.2% | -0.5% |
| Current Ratio | 0.12x | 24.65x | 0.28x | 0.05x | 8.42x |
| Quick Ratio | 0.10x | 23.05x | 0.28x | 0.04x | 6.55x |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -- | -- | -- | -- | -- | -- | -- | -6155.7% |
| Return on Assets (ROA) | -753.6% | -548.7% | -362.3% | -411.2% | -383.2% | -405.2% | -428.9% | -281.7% |
| Current Ratio | 0.11x | 0.20x | 0.24x | 0.12x | 0.15x | 0.16x | 0.22x | 0.55x |
| Quick Ratio | 0.01x | 0.01x | -- | 0.10x | 0.12x | 0.15x | 0.10x | 0.31x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
